The first quarter of 2026 was an important and exciting period for Fulcrum highlighted by the positive clinical data we ...
The FDA’s refusal-to-file decision on Moderna’s mRNA influenza vaccine has landed with extreme scrutiny after the agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results